NCT05401279 2022-08-18Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder CancerRenJi HospitalPhase 2 Unknown20 enrolled